Medical

Genoa Pharmaceuticals has announced that studies conducted in conjunction with McMaster University have shown that peak pirfenidone activity can be achieved by lung levels of the drug that remain for only a short period of time. Genoa previously announced that its GP-101 inhaled pirfenidone demonstrated greater anti-fibrotic effects with smaller doses than oral … [Read more...] about Genoa announces additional positive results for inhaled pirfenidone

Researchers from the University of St. Andrews, the University of Edinburgh, and St. Jude's Children's Research Hospital have published data demonstrating that a nasal spray designed to prevent the influenza virus from binding with receptors in the respiratory tract provided complete protection against flu in mice. The study, published in the Proceedings of the … [Read more...] about Study shows nasal spray has potential to prevent the flu

Researchers from the Icahn School of Medicine at Mount Sinai have demonstrated that a single 50 mg dose of a ketamine nasal spray could alleviate depressive symptoms in patients with treatment-resistant major depressive disorder within 24 hours. The authors conclude that, "This study provides the first controlled evidence for the rapid antidepressant effects of … [Read more...] about Study shows intranasal ketamine can provide antidepressant effects within 24 hours

Insmed has announced that in a Phase 2 clinical trial of Arikayce (formerly Arikace) inhaled liposomal amikacin for nontuberculous mycobacterial (NTM) lung infections, the product failed to produce a statistically significant reduction in mycobacterial density; however, it did meet a secondary endpoint, with significantly more patients treated with Arikayce having … [Read more...] about Mixed results in Phase 2 study of Arikayce for NTM lung infections

Israeli pharmaceutical company Kamada has initiated a US Phase 2 trial of its inhaled alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency, also known as inherited emphysema. The company also announced a delay in reporting results from a Phase 2/3 study of the product in Europe and Canada and said that it now expects to report top-line results from that … [Read more...] about Kamada initiates Phase 2 study of inhaled alpha-1 antitrypsin

GSK and Theravance have announced that results from three phase 3 studies comparing the Anoro Ellipta umeclidinium/vilanterol DPI to Advair and Seretide Diskus in COPD patients show greater improvement in lung function for patients treated with Anoro Ellipta. The three randomized, double-blind, double-dummy, parallel group studies involved a total of about 2,100 … [Read more...] about GSK announces that Phase 3 study results show Anoro Ellipta improves lung function more than Advair Diskus